EP1168919A4 - Antisense oligonukleotide mit geringem adenosin gehalt, zusammensetzungen, kit und behandlungsmethode bei erkrankung der luftwege verbunden mit bronchokonstriktion, lungenentzündung, allergien und surfactantverarmung - Google Patents

Antisense oligonukleotide mit geringem adenosin gehalt, zusammensetzungen, kit und behandlungsmethode bei erkrankung der luftwege verbunden mit bronchokonstriktion, lungenentzündung, allergien und surfactantverarmung

Info

Publication number
EP1168919A4
EP1168919A4 EP00919668A EP00919668A EP1168919A4 EP 1168919 A4 EP1168919 A4 EP 1168919A4 EP 00919668 A EP00919668 A EP 00919668A EP 00919668 A EP00919668 A EP 00919668A EP 1168919 A4 EP1168919 A4 EP 1168919A4
Authority
EP
European Patent Office
Prior art keywords
bronchoconstriction
allergies
kit
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00919668A
Other languages
English (en)
French (fr)
Other versions
EP1168919A2 (de
Inventor
Jonathan W Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina University filed Critical East Carolina University
Publication of EP1168919A2 publication Critical patent/EP1168919A2/de
Publication of EP1168919A4 publication Critical patent/EP1168919A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP00919668A 1999-04-06 2000-03-24 Antisense oligonukleotide mit geringem adenosin gehalt, zusammensetzungen, kit und behandlungsmethode bei erkrankung der luftwege verbunden mit bronchokonstriktion, lungenentzündung, allergien und surfactantverarmung Ceased EP1168919A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12795899P 1999-04-06 1999-04-06
US127958P 1999-04-06
PCT/US2000/008020 WO2000062736A2 (en) 1999-04-06 2000-03-24 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion

Publications (2)

Publication Number Publication Date
EP1168919A2 EP1168919A2 (de) 2002-01-09
EP1168919A4 true EP1168919A4 (de) 2002-03-06

Family

ID=22432865

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00919668A Ceased EP1168919A4 (de) 1999-04-06 2000-03-24 Antisense oligonukleotide mit geringem adenosin gehalt, zusammensetzungen, kit und behandlungsmethode bei erkrankung der luftwege verbunden mit bronchokonstriktion, lungenentzündung, allergien und surfactantverarmung

Country Status (9)

Country Link
EP (1) EP1168919A4 (de)
JP (1) JP2003515525A (de)
CN (1) CN1330513A (de)
AU (1) AU4031700A (de)
BR (1) BR0006019A (de)
CA (1) CA2330022A1 (de)
HK (1) HK1042017A1 (de)
IL (1) IL140054A0 (de)
WO (1) WO2000062736A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737040B1 (en) 1998-08-04 2004-05-18 Diadexus, Inc. Method and antibody for imaging breast cancer
US6730477B1 (en) 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
EP1165783A4 (de) * 1999-03-26 2002-09-11 Human Genome Sciences Inc 47 menschliche, sekretierte proteine
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
US7745420B2 (en) 2001-07-06 2010-06-29 Topigen Pharmaceutique, Inc. Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
WO2004086052A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
US7671182B2 (en) * 2003-03-31 2010-03-02 Council Of Scientific & Industrial Research Gene variants of signal transducer and activator of transcription-6 (STAT 6) variants and process of detection the same
KR101350837B1 (ko) * 2003-12-03 2014-01-14 코다 테라퓨틱스, 인크. 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
WO2006010492A1 (en) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tryptase 1 (tps1)
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
AU2005327506B2 (en) * 2004-10-20 2010-07-08 Antisense Therapeutics Ltd Antisense modulation of integrin alpha4 expression
NZ554723A (en) 2004-10-29 2009-12-24 Topigen Pharmaceuticals Inc Antisense oligonucleotides against CCR3 chemokine receptor
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
WO2006107826A2 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
EP3669878A1 (de) 2006-08-10 2020-06-24 Roy C. Levitt Lokalisierte therapie von entzündungskrankheiten der unteren atemwege mit hemmern für proinflammatorische zytokine
EP2411518A2 (de) * 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von fcerla (hochaffiner-ige-rezeptor-alpha-kette) unter verwendung von sina (short interfering nucleic acid)
JP6590790B2 (ja) * 2013-04-19 2019-10-16 エピオンティス ゲーエムベーハー 生体サンプルにおける定量的細胞組成を特定する方法
CN112969799A (zh) * 2018-09-26 2021-06-15 奥姆生命科技公司 2′fana修饰的foxp3反义寡核苷酸及其使用方法
CN109260217A (zh) * 2018-09-30 2019-01-25 深圳松乐生物科技有限公司 3`-脱氧次黄嘌呤核苷在制备用于多种疾病药品、食品或保健品中的应用
CN114591963B (zh) * 2022-05-10 2022-07-19 上海优替济生生物医药有限公司 sgRNA及利用其构建GM-CSF(-)细胞的方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010820A1 (en) * 1991-11-26 1993-06-10 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
WO1993012756A2 (en) * 1991-12-17 1993-07-08 The Regents Of The University Of California Transfection of lung via aerosolized transgene delivery
WO1994002605A1 (en) * 1992-07-22 1994-02-03 Duke University Dna encoding the human a1 adenosine receptor
WO1996040266A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for asthma
WO1996040162A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for lung diseases using antisense oligonucleotides
WO1998011211A2 (en) * 1996-09-10 1998-03-19 Hybridon, Inc. METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES
WO1998023294A1 (en) * 1996-11-26 1998-06-04 East Carolina University Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
WO2000009525A2 (en) * 1998-08-03 2000-02-24 East Carolina University Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
CA2236825A1 (en) * 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
DK1009413T3 (da) * 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010820A1 (en) * 1991-11-26 1993-06-10 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
WO1993012756A2 (en) * 1991-12-17 1993-07-08 The Regents Of The University Of California Transfection of lung via aerosolized transgene delivery
WO1994002605A1 (en) * 1992-07-22 1994-02-03 Duke University Dna encoding the human a1 adenosine receptor
WO1996040266A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for asthma
WO1996040162A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for lung diseases using antisense oligonucleotides
WO1998011211A2 (en) * 1996-09-10 1998-03-19 Hybridon, Inc. METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES
WO1998023294A1 (en) * 1996-11-26 1998-06-04 East Carolina University Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
WO2000009525A2 (en) * 1998-08-03 2000-02-24 East Carolina University Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LOAKES D ET AL: "5-NITROINDOLE AS AN UNIVERSAL BASE ANALOGUE", NUCLEIC ACIDS RESEARCH, vol. 22, no. 20, 1994, pages 4039 - 4043, XP000999195, ISSN: 0305-1048 *
METZGER W JAMES ET AL: "Oligonucleotide therapy of allergic asthma.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 104, no. 2 PART 1, August 1999 (1999-08-01), pages 260 - 266, XP001024505, ISSN: 0091-6749 *
NICHOLS R ET AL: "A UNIVERSAL NUCLEOSIDE FOR USE AT AMBIGOUS SITES IN DNA PRIMERS", NATURE, vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 492 - 493, XP000560346, ISSN: 0028-0836 *
OHTSUKA E ET AL: "AN ALTERNATIVE APPROACH TO DEOXYOLIGONUCLEOTIDES AS HYBRIDIZATION PROBES BY INSERTION OF DEOXYINOSINE AT AMBIGUOUS CODON POSITIONS", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol. 260, no. 5, 10 March 1985 (1985-03-10), pages 2605 - 2608, XP002031938 *
RAHMAN M SAYEEDUR ET AL: "Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenine in vivo and in vitro.", MUTATION RESEARCH, vol. 377, no. 2, 1997, pages 263 - 268, XP001024479, ISSN: 0027-5107 *

Also Published As

Publication number Publication date
EP1168919A2 (de) 2002-01-09
BR0006019A (pt) 2001-03-13
CN1330513A (zh) 2002-01-09
CA2330022A1 (en) 2000-10-26
JP2003515525A (ja) 2003-05-07
WO2000062736A2 (en) 2000-10-26
IL140054A0 (en) 2002-02-10
WO2000062736A3 (en) 2001-10-11
AU4031700A (en) 2000-11-02
HK1042017A1 (zh) 2002-08-02

Similar Documents

Publication Publication Date Title
EP1168919A4 (de) Antisense oligonukleotide mit geringem adenosin gehalt, zusammensetzungen, kit und behandlungsmethode bei erkrankung der luftwege verbunden mit bronchokonstriktion, lungenentzündung, allergien und surfactantverarmung
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
AU2001238653A1 (en) Method for treating hashimoto's thyroiditis
MX236443B (es) Combinacion de bacterias de acido lactico y su uso para la prevencion y/o tratamiento de infecciones y condiciones inflamatorias.
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
WO2000074662A3 (en) Arthritis treatment
HUP0105302A3 (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation
GB9930691D0 (en) Improvements relating to double-stranded RNA inhibition
ZA991053B (en) Method and composition for treatment of inflammatory conditions.
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
DZ3027A1 (fr) Composés et procédés pour le traitement de l'asthme, de l'allergie et des troubles inflammatoires.
HUP0301791A3 (en) Method for the treatment of climacteric disorders in women during or after the menopause
AU2003247303A1 (en) Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
AU9527001A (en) Treatment of T cell disorders
EP1554033A4 (de) Verbesserte zusammensetzungen zur entfernung von randperlen von halbleiterbelastungspufferbeschichtungen und verfahren zu ihrer verwendung
HUP0202345A3 (en) Method of purifying water, suitable bacteria for the method and use thereof
EP1161255A4 (de) Verfahren und mittel zur behandlung erektiler dysfunktion
FR2790979B1 (fr) Procede et installation pour le traitement des vases
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
AU3593599A (en) Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
PL355261A1 (en) Method and compositions for treating pulmonary diseases
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
AU1133901A (en) Method of treating metabolic disorders
MA26592A1 (fr) Procede et medicament utilisant des composes cycliques, pour le traitement de la bronchopneumopathie chronique obstructive

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020117

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 6/00 A

17Q First examination report despatched

Effective date: 20020405

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20041017